An Open-Label, Two-Part, Phase 1/2a, Crossover Study to Determine the Absolute Bioavailability and Pharmacokinetics of Oral Immediate-Release Doses of OCR‑002 in Subjects With Varying Degrees of Cirrhosis
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Ornithine phenylacetate (Primary) ; Ornithine phenylacetate (Primary)
- Indications Liver cirrhosis
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Mallinckrodt plc; Ocera Therapeutics
Most Recent Events
- 01 Mar 2021 Study phase changed from I/II to I.
- 26 Feb 2019 New trial record